Eli Lilly购买了Meira GTx的童年失明基因治疗的全球权利, Eli Lilly buys global rights to MeiraGTx’s gene therapy for childhood blindness, paying $75M upfront with potential for $400M more.

Eli Lilly获得了Meira GTx的AAV-AIPL1基因治疗方案的专属全球权利,该方案针对的是Leber先天性畸形4型,一种罕见的导致儿童失明的遗传眼病。 Eli Lilly has acquired exclusive global rights to MeiraGTx’s AAV-AIPL1 gene therapy program, which targets Leber congenital amaurosis 4, a rare genetic eye disorder causing childhood blindness. 这笔交易包括预付给Meira GTx的7 500万美元预付款,潜在的里程碑付款超过4亿美元,以及未来销售的特许权使用费。 The deal includes an upfront $75 million payment to MeiraGTx, potential milestone payments exceeding $400 million, and royalties on future sales. 早期临床数据显示,所有11名受治疗的4岁以下出生时失明儿童的视力都有改善。 Early clinical data showed vision improvement in all 11 treated children under four born blind. 利利还获得了MeiraGTx的先进基因治疗平台,包括新型囊体,人工智能设计的促进剂,以及用于控制眼中的蛋白质生产的核突开关系统. Lilly also gains access to MeiraGTx’s advanced gene therapy platforms, including novel capsids, AI-designed promoters, and a riboswitch system for controlled protein production in the eye. 合作加强了Lilly的遗传医学管道,并可从林业发展局加速审查儿科失明疗法的试点方案中受益。 The collaboration strengthens Lilly’s genetic medicine pipeline and could benefit from an FDA pilot program for faster reviews of pediatric blindness therapies. MeiraGTx的股价在市场前贸易中上升了15%。 MeiraGTx’s shares rose 15% in premarket trading.